Treatment for co-occurring posttraumatic stress disorder and substance use disorders among veterans and civilians: A test of causally moderated comparative effectiveness.

Psychol TraumaOct 20, 2025 (epub)
Clinical ResearchPsychiatryOpen access

Shannon M Blakey, Antonio A Morgan-López, Alexander C Kline et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis used secondary analyses of psychotherapy-arm data from 26 randomised controlled trials involving 3,228 veterans and civilians with co-occurring posttraumatic stress disorder (PTSD) and substance use disorders (SUD). It examined whether veteran status moderated treatment outcomes. Trauma-focused psychotherapy for PTSD and integrated trauma-focused psychotherapy for PTSD and SUD were each superior to treatment as usual for alcohol-use severity, with stronger effects among veterans than civilians. Veteran status did not appear to modify comparative effects on PTSD or drug-use severity.

Key findings

  • Both trauma-focused psychotherapy and integrated trauma-focused psychotherapy outperformed treatment as usual for alcohol-use severity; the effect was stronger among veterans.
  • There was no evidence that veteran status modified treatment effects on PTSD severity relative to treatment as usual.
  • There was no evidence that veteran status modified treatment effects on drug-use severity relative to treatment as usual.

Why it matters

The findings suggest that veteran status may help explain variation in alcohol-use outcomes when treating people with co-occurring PTSD and SUD. They also distinguish this outcome from PTSD and drug-use severity, for which differential response by veteran status was not supported. This may inform future research on matching patients to treatments while underscoring that subgroup effects should be interpreted in light of the evidence.

What to keep in mind

The analyses were secondary and limited to psychotherapy-arm data from the included trials; the abstract reports no quantitative effect estimates.

Source

Published in Psychol Trauma. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.